Addressing Undertreatment and Health Equity in Aortic Stenosis Using an Integrated EHR Platform - Trial NCT06099665
Access comprehensive clinical trial information for NCT06099665 through Pure Global AI's free database. This phase not specified trial is sponsored by Tempus Labs and is currently Not yet recruiting. The study focuses on Aortic Valve Stenosis. Target enrollment is 1058 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tempus Labs
Timeline & Enrollment
N/A
Jan 01, 2024
Dec 01, 2024
Primary Outcome
Establish impact of automated alerts on the hierarchical composite endpoint of aortic valve repair/replacement (AVR) or follow-up visit with a multi-disciplinary heart team (MHT).
Summary
This multi-center, prospective, cluster-randomized controlled trial will evaluate Mpirik
 automated notifications as an intervention to support identification and evaluation of
 patients possibly indicated for Aortic Valve Replacement (AVR). This study will evaluate the
 impact of Mpirik automated notifications on: (1) AVR utilization (including time to AVR); and
 (2) multidisciplinary heart team clinic evaluation (including time to evaluation) for
 patients with definitive or possible severe AS on echocardiogram. These endpoints will also
 be examined within and between assigned groups according to race, ethnicity, sex, and
 geography.
 
 The primary question that will be answered:
 
 Do automated alerts sent to clinical providers decrease under-treatment of severe aortic
 stenosis?
 
 The study will compare the rate of clinical follow-up and aortic valve surgery in a control
 group (no alerts sent) to a treatment group (alerts sent to an appropriate care provider).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06099665
Non-Device Trial